<313989F193FA967B88E397C396F28A7789EF944E89EF5F8FB4985E8F57315F914F95745F E696E6464>
|
|
|
- あいと ねぎたや
- 7 years ago
- Views:
Transcription
1 1024 P1-001 P P2-001 P2-501 CJK-01 CJK
2 1024 1F P1-001 P1-002 P1-003 P1-004 P1-005 P P1-007 P1-008 P1-009 P1-010 P1-011 P1-012 P P P1-015 P1-016 P1-017
3 19 P1-018 P1-019 GS1-Databar P1-020 P1-021 P P1-023 RSS P1-024 P1-025 P1-026 P P1-028 P1-029 P1-030 P1-031 P P1-033 P1-034 P
4 P1-036 P1-037 P1-038 Mg P1-039 P1-040 GFReGFR 2 P1-041 P1-042 P P1-044 P P1-046 P1-047 P1-048 P1-049 P1-050 P1-051
5 19 P1-052 TPN 3 P1-053 P P1-055 P1-056 P1-057 HIV 2 HIV2 P1-058 P1-059 P1-060 P1-061 P1-062 P1-063 P1-064 P1-065 P1-066 P1-067 P1-068
6 P1-069 P F P1-071 P1-072 PVC/TOTM -2 ph P1-073 PVCTOTM P1-074 P1-075 TE P1-076 AAOTC P1-077 P1-078 ISO9001: F P1-079 P P1-081 EG-MAIN GX P1-082 P1-083
7 19 P1-084 P1-085 P1-086 P1-087 P1-088 P F P P1-091 P P1-093 P1-094 P1-095 P1-096 P1-097 P1-098 ASO ASO P1-099
8 P1-100 P1-101 P1-102 Helicobacter pylori P F P1-104 P1-105 PT-INR P1-106 P1-107 P1-108 P1-109 TS-1 P1-110 UGT1A1 P1-111 UGT1A1*6weekly Taxol+CPT-11 P P1-113 R-CHOP P1-114 P1-115 FEC100
9 19 P1-116 P1-117 P1-118 P1-119 P1-120 P1-121 P1-122 mfolfox6/folfiri P1-123 P1-124 P1-125 FEC100 P1-126 P1-127 P1-128 P1-129 P1-130 P1-131
10 P1-132 P1-133 P1-134 P1-135 P1-136 P1-137 P1-138 P1-139 mfolfox6 P1-140 P1-141 P1-142 P1-143 P1-144 P1-145
11 F P1-146 GFR P1-147 P1-148 CDDP+GEM P1-149 S-1 P1-150 High dosefp P1-151 P CHOPvincristine P1-153 S-1 P1-154 P1-155 P1-156 P1-157 FOLFOXFOLFIRI P1-158 DCTC P1-159 P1-160 FOLFOX4 P1-161 P1-162
12 P1-163 P1-164 GC P1-165 P1-166 Gemcitabine+ Fluorouracil+CisplatinGFP P1-167 P1-168 P1-169 S-1CDDP NST P1-170 FOLFOX P1-172 P1-173 QOL P1-174 P1-175 R-CHOPR-THP-COP P F P1-177 S-1UFT5-FU P1-178 P1-171 Bortezomib
13 19 P1-179 P1-180 P1-181 EGFR-TKI P1-182 P1-183 G-CSF P1-184 P1-185 P1-186 P1-187 P1-188 P1-189 CBDCA+WeeklyPTX P1-190 P1-191 P HT3 P P1-194 FECEC P1-195
14 P1-196 P1-197 VAS P1-198 VAS P1-199 P1-200 P1-201 P1-202 FOLFOX P1-203 P1-204 mfolfox6 1 P1-205 Cetuximab P1-206 BEP P1-207 P1-208 P1-209 P1-210 Olanzapine P1-211
15 19 P1-212 mfolfox6oxaliplatin P P1-214 P1-215 FN P1-216 Vinorelbine P1-217 P1-218 P1-219 P1-220 P P1-222 R-CHOP P1-223 P1-224 Bortezomib P1-225 P1-226
16 P1-227 P1-228 Trastuzumabinfusion reaction P1-229 P1-230 P1-231 FACT/GOG- NtxV4.0 P1-232 mfolfox6 P FU P1-234 P1-235 Cetuximabinfusion reaction P1-236 P1-237 B12 P1-238 P1-239 P1-240 S F P1-241
17 19 P1-242 P1-243 P1-244 P1-245 P1-246 WHO P1-247 P1-248 P1-249 P1-250 P1-251 MT P1-252 P1-253 P1-254 P1-255 P1-256 P1-257
18 P1-258 P1-259 P1-260 P P1-262 P1-263 P1-264 P1-265 P1-266 P1-267 P1-268 P1-269 P1-270 P1-271 P1-272
19 19 P1-273 P1-274 P1-275 P1-276 P1-277 P1-278 P1-279 P1-280 P1-281 PCA P1-282 P1-283 P F P1-285 P1-286 P1-287 P
20 P1-289 P1-290 P P1-292 closed systemclave Oncology System P1-293 P1-294 P1-295 P1-296 P1-298 P1-299 EGFR P1-300 P1-301 P1-302 P1-303 P1-304 P1-305 P1-297
21 19 P1-306 egfr P1-307 P1-308 P1-309 P1-310 P1-311 PhaSeal P1-312 Gemcitabine P1-313 P1-314 P1-315 P1-316 P1-317 P P1-319 TS-11 P1-320 EGFRCetuximab P1-321 P FU46
22 P1-323 P1-324 Sorafenib1 P1-325 Cancer board P1-326 P1-327 P1-328 P1-329 P1-330 P1-331 P1-332 P1-333 Conditioning rejimen P1-334 P1-335 P1-336 thalidomide P1-337 P1-338
23 19 P1-339 P1-340 P1-341 P P1-343 ACRelative Dose Intensity P1-344 FEC100 P1-345 P1-346 P1-347 P1-348 PDGFR P1-349 P1-350 P1-351 P1-352 P1-353 P1-354 KCP-4
24 P1-355 P1-356 P1-357!? P1-358 P1-359 P mg P1-361 P1-362 P1-363 P1-364 P1-365 P1-366 P F P1-368 P1-369 MRSA P1-370 P1-371 Linezolid
25 19 P1-372 P P P P1-376 PK-PD P1-377 P1-378 P1-379 Febrile neutropeniamic P1-380 PK/PDEtest P1-381 P1-382 P1-383 P P1-385 MRSA P1-386 P1-387 MRSA
26 P P1-389 de-escalation P1-390 PK/PD P1-391 / P1-392 MRSA P1-393 P1-394 P1-395 LVFX P1-396 P1-397 P1-398 P1-399 P1-400 P1-401 MRSA P P1-403 P1-404 ICT MRSAMRSA P1-405 MRSATDM
27 19 P1-406 GVHD P F P1-408 P1-409 P P1-411 Anatomical Therapeutic Chemical/Defined Daily Dose system 1 P1-412 ATC/DDD system 1 P1-413 P1-414 P1-415 P /082008/09 P1-417 P1-418 TDM P1-419 P1-420
28 P1-421 MRSA VCM P P1-423 P1-424 P P1-426 P1-427 P1-428 ICTMRSA P1-429 P1-430 P1-431 P1-432 P1-433 CCUMRSA P1-434 P1-435 DPC P1-436
29 19 P1-437 P1-438 P1-439 P1-440 P1-441 P1-442 P1-443 A/H1N1 P1-444 AH1N1 P1-445 P F P C P1-448 P1-449 Beers Criteria 2 P1-450 P1-451
30 P1-452 P1-453 P1-454 P F P1-456 SGA P1-457 P1-458 P1-459 P1-460 P P1-462 NaHt P1-463 P1-464 P1-465 P1-466 P1-467 TDM
31 19 P1-468 P1-469 CP P1-470 P1-471 P1-472 Leu-Ile P1-473 P1-474 P1-475 P1-476 QOL1 P1-477 P1-478 P F P1-480 P1-481 P1-482
32 P1-483 RATocilizumab P1-484 VTE P1-485 P1-486 P1-487 P1-488 P1-489 P1-490 P1-491 P1-492 P P P CPEG-IFN-2b Ribavirin Rebound Index P1-496 C DFPPIFN P1-497 P1-498
33 19 P1-499 P1-500 P1-501 P1-502 P1-503 sofalcone P1-504 P1-505 RA MTX P1-506 P1-507 P1-508 TNF- P1-509 P1-510 B P1-511 T P1-512 CPEG-IFN-2aPEG- IFN-2bQOL P1-513 P1-514
34 P P1-516 P1-517 P1-518 EPA P1-519 HIV P1-520 HAART F P1-521 P1-522 P1-523 P1-524 P1-525 P1-526 BFH P1-527 P1-528 P1-529 P1-530
35 19 P1-531 P1-532 P F P1-534 PCa P1-535 P1-536 P1-537 P1-538 P1-539 P1-540 CKD P1-541 P1-542 CKDARB P1-543 CKD P1-544 P1-545
36 1024 3F P1-546 GCP P1-547 GMP P1-548 P1-549 P1-550 IRB P1-551 P F P1-553 P1-554 P1-555 P1-556 P1-557 Tris2-ethylhexylTrimellitate P1-558 OD P1-559 LDL-Cholesterol
37 19 P1-560 : 2008 P1-561 P1-562 P P1-564 P aminolaevulinic acid P1-566 P1-567 P F P mg P2-002 P2-003 P2-004 P2-005 P2-006
38 P DI/RM P2-008 P2-009 P2-010 P2-011 P2-012 P2-013 P2-014 P2-015 P2-016 CYP P2-017 P2-018 K P2-019 OTC P2-020 P2-021 P2-022 P2-023
39 19 P2-024 P F P2-026 P2-027 P2-028 VTR P2-029 P2-030 P2-031 P2-032 TERMS P2-033 P2-034 P2-035 P2-036 P2-037 P2-038 P2-039 P
40 P2-041 IBD P2-042 P2-043 P2-044 P2-045 P2-046 P2-047 P2-048 Ver.1 P2-049 P2-050 P P2-052 RAMTX P2-053 P2-054 P2-055 P2-056 P2-057 P2-058
41 19 P2-059 P2-060 P2-061 P2-062 P2-063 P2-064 P2-065 P2-066 P P2-068 P2-069 P2-070 Vancomycin P2-071 P P2-073 PTP P2-074 P2-075 P2-076 Beers List
42 P2-077 P F P2-079 P2-080 ASCO P2-081 P2-082 P2-083 P P2-085 P F P2-087 P2-088 P2-089 OTC P2-090 P2-091 P2-092
43 19 P2-093 P2-094 PT-INR P2-095 P2-096 P P2-098 P2-099 P2-100 P2-101 P2-102 WarfarinTS-1 P2-103 INR F P2-104 PPIH2 P2-105 P2-106 Web P2-107 Xa
44 P2-108 P2-109 P2-110 HITHeparin-Induced Thrombocytopenia P2-111 P2-112 P2-113 P2-114 VCM P P2-116 P2-117 P2-118 P2-119 P2-120 P2-121 P2-122 P2-123 P2-124 L-asparaginaseGrade4 1
45 19 P2-125 P2-126 P2-127 P2-128 P2-129 P g P2-133 P2-134 Infusion reactiontrastuzumab P2-135 CsA Pioglitazone P2-136 P P2-138 P2-131 DLST P F P2-139 No.6 P2-140
46 P2-141 P2-142 P2-143 P2-144 P2-145 P2-146 P2-147 P2-148 P2-149 P2-150 P2-151 TDM P2-152 P2-153 P2-154 P2-155 P2-156 P2-157 P2-158
47 19 P2-159 P2-160 P F P2-162 II P2-163 P F P2-165 P2-166 P2-167 P2-168 OD P2-169 P2-170 P P2-172 MRI
48 P2-173 Na 1 P2-174 P2-175 P2-176 P2-177 P2-178 IF P2-179 P2-180 CR CR P2-181 P2-182 P2-183 P2-184 MR P2-185 P2-186 P2-187
49 19 P P P2-190 P F ICU P2-192 ICU P2-193 ICU P2-194 P2-195 PCAPatientcontrolled analgesia P2-196 ICUCCUSCU P F P2-198 P2-199 P2-200 P2-201 IRS 2 P2-202
50 P P2-204 P2-205 P2-206 P2-207 P P2-209 P2-210 Q1. zig P F P2-212 P2-213 P2-214 PEG P2-215 D P P P2-218
51 19 P2-219 PLGA P2-220 Mohs paste P2-221 Mohs P2-222 Mohs P2-223 P2-224 P F P2-226 P450P- P2-227 P P2-229 / - P2-230 HPLC - P2-231 P2-232 MRP2ABCC2 P2-233 RNA30b, 93, 98, 126, 210
52 P2-234 N1-L F TDM P2-235 P2-236 P2-237 P2-238 In vitro P2-239 TDM P2-240 P2-241 C P2-242 MS-Excel P2-243 CHDF 1 P2-244 TDM P2-245 TDM P2-246 PK/PD P2-247 P2-248 VCM
53 19 P2-249 P2-250 MRSA P2-251 P2-252 P ,11-1 P2-254 P2-255 P2-256 TDM P2-257 P2-258 VCM P2-259 TDM P2-260 P2-261 /ODS P2-262 PK/PD P2-263 TDM P2-264 P CD4 + IMMUKNOW 1
54 P2-266 P2-267 MRSA P2-268 TDM P2-269 P2-270 Bayesian P2-271 C P2-272 egfr P2-273 CLIA P2-274 CAPD TDM P2-275 P2-276 Cmax/MIC P2-277 TDMGFR P2-278 VCM P2-279 P2-280 P2-281 TDM P2-282
55 19 P2-283 MRSA P2-284 MRSATDM P2-285 ADVIA Centaur CP P2-286 P2-287 HPLC F P2-288 P2-289 HLA-A 3303 * P2-290 P2-291 SLC29A1 mrnaslc29a1 P2-292 II P2-293 AripiprazoleCYP2D6 P2-294 NR4A F NST P2-295 P2-296
56 P2-297 P2-298 P2-299 P2-300 P2-301 P P2-303 P2-304 P2-305 P2-306 NST P2-307 TPNNST P2-308 P2-309 P2-310 P2-311 ICU P2-312
57 19 P2-313 P2-314 NST P2-315 P2-316 P2-317 NST P2-318 P2-319 NSTICTCDAD F P2-320 P2-321 P P2-323 P2-324 P2-325 P2-326
58 P2-327 P2-328 P2-329 SU P2-330 P2-331 P2-332 P2-333 P2-334 P2-335 P P2-337 P Basal-supported Oral TherapyBOT P2-339 P2-340 P2-341 P2-342 P2-343
59 19 P2-344 P2-345 P P2-347 P2-348 P2-349 P2-350 TM F P2-351 P2-352 P2-353 P P P2-356 P2-357
60 1025 3F P2-358 P2-359 P2-360 ICU P2-361 P2-362 HIE P2-363 P2-364 P2-365 P2-366 P2-367 ICU P2-368 NICU P2-369 P F P
61 19 P P2-373 P2-374 P2-375 P2-376 P2-377 P2-378 P F DPC P2-380 P2-381 DPC P2-382 DPC P2-383 DPC P F P2-385
62 P2-386 P2-387 P2-388 P2-389 P P2-391 P2-392 P F P P2-395 TS-1 P P2-397 P P2-399
63 19 P P2-401 P2-402 P2-403 P2-404 P2-405 P2-406 P P2-408 P2-409 P2-410 HIV P2-411 P2-412 P2-413 P2-414 P2-415
64 P2-416 CKD F P2-417 P2-418 P2-419 P2-420 P2-421 P2-422 P2-423 P2-424 P2-425 P2-426 P2-427 SBOs P2-428 P2-429 PBL P2-430
65 19 P P2-432 P2-433 P2-434 WEB 2 P2-435 WEB 3 P P P2-438 P2-439 SGD P2-440 OSCE2 P2-441 P2-442 FD P2-443 P2-444 P2-445
66 P P2-447 P2-448 P2-449 P P P2-452 P2-453 P F P2-455 P2-456 OSCE P2-457 P2-458 P P2-460 P2-461
67 19 P2-462 P2-463 P2-464 P SP P2-466 OSCE P2-467 OSCE P2-468 PBL- P2-469 P2-470 P PBLProblem-Based Learning P P2-473 P P2-475 P2-476 P2-477
68 P2-478 P2-479 P2-480 P2-481 P2-482 P2-483 PBL 2 P2-484 OSCE P2-485 P2-486 GP3 P2-487 GP2 P2-488 GP1 P2-489 P2-490 P2-491 P2-492 P
69 19 P F P2-495 P2-496 OJT P2-497 P2-498 OJTOffJTOJT P2-499 P2-500 P2-501 Problem Based LearningPBL F CJK-01 Physical Compatibility of a Gabexate with Selected Medications CJK-02 Drug-induced hyperbilirubinemia and the clinical influencing factors CJK-03 Pharmacists Clinical Interventions in Chemotherapy CJK-04 The Effect of Aprepitant Regimen on the Prevention of High-Dose Cisplatin-Induced Nausea and Vomiting CJK-05 Analysis of Prescription the prevention of Secondary MI in Kyung Hee University Medical Center in Korea (KHMC)
70 CJK-06 Changes of Insoluble Particles in 6 Common Used Traditional Chinese Medicine Injections after mixed with Transfusions of Different Companies CJK-07 Discussion of the Outpatient Pharmacy Working Model based on Pharmacy Information management System (PIS) CJK-08 Pharmacokinetics and distribution of Pegylated liposomal doxorubicin after spleen injection in mice CJK-12 The molecular mechanism of inhibitory effect of deferoxamine on amyloid- deposition in Alzheimer transgenic mouse brain CJK-13 The preparation of a compound nerve conduit and it effect on the regeneration of defected peripheral nerve CJK-14 Research on the effective utilization of drug information using ICT (Information & Communication Technology) CJK-09 Study of inhibitory effect of low-dose chemotherapy drugs on the growth of glioblastoma cell line U87 CJK-10 The clinical pharmacists accelerate the rational medication use by medical order-checking CJK-11 Study of anti-inflammatory effect and protection against hepatic injury on different proportions of - and -glycyrrhizic acids
<313989F193FA967B88E397C396F28A7789EF944E89EF5F8FB4985E8F57315F914F95745F3039303931342E696E6464>
1024 O1-001 O1-010 O2-001 O2-010 O3-001 O3-010 O4-001 O4-010 /TDM 1000 O5-001 O5-010 / O6-001 O6-010 //NST/ O7-001 O7-014 //// O8-001 O8-014 O9-001 O9-014 /// 1400 O10-001 O10-014 //DPC// 1025 O11-001
16,,, 38, (1990) 17 J Toxicol Sci, 15 (Suppl IV), (1990) 18 Cognitive enhancers ( ), 13, (1990) ,, 120, (1991) 20,
1974 1,, 25, 1385-1391 (1974) 1983 2,, 34, 1451-1454 (1983) 1984 3,, Phencyclidine (PCP),, 4, 133-147 (1984) 1985 4,,,, 11, 132-146 (1985) 1986 5 Phencyclidine Angel Dust, 138, 178-180 (1986) 6, 6, 660-666
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
21 8 20 70 1 1 2 1 1 20 12 22 16201835 2 21 1 21 15001910 3 21 2 23 15001750 4 21 3 23 15002030 5 21 4 27 15102010 6 21 6 15 15002110 7 21 7 27 15001910 2 3 3 21 3 21 4 2 4 1 2 1 2 312 4 3 1 2 3 4 2
indd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
24 24 CTZ 5HT 3 (), (), () () () NK1, etc CTZchemoreceptor trigger zone () 5HT 3 5HT 3 7, (1), (2), (1), 15HT 3, ,,,( ), CDDP, () (CDDP) NSCLC PS 0-2 CDDP >50mg/m2 OND 8mg DEX 4mg R (n=530) OND 8mg DEX
2009年度 東京薬科大学 薬学部 授業計画
2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy
untitled
CONTENTS 01 02-03 04-05 06-07 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48-49 50-51 52 01 02 Mishima,Michiaki 03 04 05 06 07 09 10 11
untitled
NTT 143-8540 5-21-16 Tel 03-3762-4151 Fax: 03-5493-5417 E-mail health@med.toho-u.ac.jp URL http://jhmtokyo.umin.jp 2 5 6 7 8 9 10 13 17 25 31 32 33 35 38 41 91 115 3 4 9 NPO 1999 5300 DPC BSC 9 2009 2
総 説 6 6 PIMs P S J 7
2018 10 1-6 総 説 2018 P S J 1 2018 10 7-13 総 説 6 6 PIMs P S J 7 2018 10 19-29 誌上シンポジウム JASDS DSM 1997 2012 15 DSM DSSP JASDS DSM DSSP P S J 19 2018 10 30-34 誌上シンポジウム ADME 30 Pharmacy Society of Japan 2018
Jpn Pharmacol Ther vol. 31 no Panos Kanavos Director, International Health Policy, Dept. of Social Policy & LSE Health, London School of Econ
Panos Kanavos Director, International Health Policy, Dept. of Social Policy & LSE Health, London School of Economics 1. Introduction ad hoc European Union: EU third party (a) (b) (c) (d) (e) value added
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
MV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO
乳がん患者の放射線皮膚炎に対するスキンケアの指導の実際 がん放射線療法看護認定看護師とがん放射線治療に携わる看護師との比較 Educating practice of skin care for radiodermatitis of breast cancer patients: Comparison of the nurses with certified nurse in radiation therapy
基本 CMYK
Information Communication Technology ICT = Information and Communication Technology 04 16 26 % 5 3 554 1,717 1,4 1,397 3,001 52.5 56.1 52.2 53.6 48.1 47.6 47.9 % 506 470 506 1,482 1,708 1,530 3,238 47.4
untitled
PS3 10% 2-1 2-2 2-3 2 23 2-4 1 2 3 4 2-5 2.3.1 1 24 812 2-6 5 5% : (CVC) 5 2-7 CTZ 24 24 2-8 2.3.2 23 5HT3 12 2-9 2.3.3 12 12 23 710 13 5-FU 2-10 2.3.4 24 10 20 5-FU 2-11 2-12 (CTZ) 5HT3 H1 Achm (CTZ)
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
e-seeds jp A A Kumamoto University Teaching Online MEMedical Engineering e 17 - - Medical Engineering e Web - WG -- - S A B Web e-seeds jp e-seeds jp SAB e - - - - H H ISO ISO FD
. No.1 Copyright: Takahiro Kiu No.1 (UMIN Cente
. No.1 No.1 No.2 No.3 No.4 No.5 No.6 , No.7 No.8 Research http://www.umin.ac.jp/research/ Education http://www.umin.ac.jp/education/ Multipurpose http://www.umin.ac.jp/multi-purpose/ AC - Academic societies
2014 6 7 12 原 著 S 1, 2 1 1 1 1 2 1 2 2012 6 1 2013 8 26 S S S 148 4 72 49 6 / 60 7 / 12 20 7 / S S OTC 7
2014 6 1 6 Review Article Proposal for Outcome Verification of Iyakubungyo and Future Directions Miwako Kamei 1, Mitsuko Onda 2, Kazuko Akagi 3, Tomohide Akase 4, Noriko Fukushima 5, Noriko Miyamoto 6
08医療情報学22_1_水流final.PDF
22 (1), 702002: 59 59- The Problem of Nursing Common Language for the Information Sharing in Clinical Practice The fact-finding in regard to the correspondence between name and content of nursing action
32 TEL: 0959-52-3000 FAX: 0959-52-4467 Email: nkh@orange.ocn.ne.jp URL: http://www.kamigoto-hospital.jp/ 1 73 MRI IT IVR PTCA 74 MC CT) NECMega-Ork 75 Web HTLV-IATL 2 ICU Holter MD-C T MRIX DSAFCR 3 4
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
Vol. 48 No. 3 Mar PM PM PMBOK PM PM PM PM PM A Proposal and Its Demonstration of Developing System for Project Managers through University-Indus
Vol. 48 No. 3 Mar. 2007 PM PM PMBOK PM PM PM PM PM A Proposal and Its Demonstration of Developing System for Project Managers through University-Industry Collaboration Yoshiaki Matsuzawa and Hajime Ohiwa
1
1 3 2008 4 19 69 20 82 12241251 IRB IRB CRC CRC 2000 EDC 2 baseline 19 20 Network draft protocol feasibilitystudy 20 CCR 1 9 timeline 40 coordinating centre Minnesota e-learning seminar 3 114 125 144 67
設置の趣旨等を記載した書類
232011 4 ... 1... 4... 5... 5... 9... 9... 11... 12... 12... 14... 14... 15... 15... 19 161639 8 8 1 9 1 61994 4 122000 4 2 142002 4 15 2003 4 192007 4 20 172005 4 100 1,000 510 172005 222010 1 192007
<91E F193FA967B97D58FB B2D8FB4985E8F572E696E6464>
36 35 12 10 4 1 1300 1330 26 10 5 1 1330 1400 26 10 4 1 1400 1430 10 5 1 1400 1430 10 4 1 1430 1530 1 10 5 1 1430 1530 2 10 4 1 1100 1130 EL-1 1 10 4 2 1100 1130 EL-2 2 10 4 2 1500 1530 EL-3 3 2015 10
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
<93C195CA D834F E696E6464>
45 I I Diabetes and Heart: Insight by Imaging Juhani Knuuti Turku PET Centre, Turku University Central Hospital II I Development and Application of Beta-Amyloid Imaging Agents Chet A. Mathis Department
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
YC41S213.ec Jpn Pharmacol Ther vol. 41 supplement 2013 A Proposal for Optimization of Clinical Trial by Central Monitoring System Consolidat
A Proposal for Optimization of Clinical Trial by Central Monitoring System Consolidation by Applying the Operation Center and Electronic Data Sharing System 2.0 1 2 2 3 4 5 6 7 8 8 9 10 11 12 13 14 1 1
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
92 adenocarcinoma SE ly2 v2 n0 pstage KRAS XX XX 2 1 mfolfox6 l-lv 300 / L-OHP 130 / 5-FU 600 / 5-FU 3,600 / FU/LV de Gramont
92 91 95 2016 5-FU 1 1) 2) 3) 2) 2016 1 5 2016 3 4 FOLFIRI Bevacizumab Bev 5-FU NH3 1 NH 3 5-FU NH 3 Key words: 5-FU : NH 3 orotate phosphorylase OPRT thymidylate synthase TS dihydropyrimidine dehydrogenase
2 10 The Bulletin of Meiji University of Integrative Medicine 1,2 II 1 Web PubMed elbow pain baseball elbow little leaguer s elbow acupun
10 1-14 2014 1 2 3 4 2 1 2 3 4 Web PubMed elbow pain baseball elbow little leaguer s elbow acupuncture electric acupuncture 2003 2012 10 39 32 Web PubMed Key words growth stage elbow pain baseball elbow
A. B. C. D. E. GIO SBO, MR Medical representative CRO contract research organization,,, HIV MR MR MR MR MR CRO contract research organization CRA CRO CRA I IV, CBT OSCE CBT computer based testing OSCE
糖尿病薬の保険調剤 留意事項など
E-mail; west@gifu-shiya k u.ne t supported by 2 Road traffic accident risk in patients with diabetes mellitus receiving blood glucose-lowering drugs. Prospective follow-up study S. Skurtveit*, H. Strøm*,
untitled
11-19 2012 1 2 3 30 2 Key words acupuncture insulated needle cervical sympathetick trunk thermography blood flow of the nasal skin Received September 12, 2011; Accepted November 1, 2011 I 1 2 1954 3 564-0034
2 22006 2 e-learning e e 2003 1 4 e e e-learning 2 Web e-leaning 2004 2005 2006 e 4 GP 4 e-learning e-learning e-learning e LMS LMS Internet Navigware
2 2 Journal of Multimedia Aided Education Research 2006, Vol. 2, No. 2, 19 e 1 1 2 2 1 1 GP e 2004 e-learning 2004 e-learning 2005 e-learning e-learning e-learning e-learning 2004 e-learning HuWeb 2005
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
1 ご挨拶・講演等.indd
8 28 D 1313 9 00 9 40-1 O-001 O-002 O-003 LDL O-004 LDL LDL O-005 8 28 D 1313 9 40 10 20-2 O-006 O-007 O-008 B 1 O-009 O-010 - 8 28 D 1313 10 20 10 52-1 O-011 O-012 5 O-013 3 O-014 CKD 24 8 28 D 1313 10
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
“÷Œò›ï48
48 37 773 1 18 100 214 1 50 2 5 7 OSCE (Objective Structured Clinical Examination) 8 10 14 15 16 6 19 20 21 21 22 22 25 26 26 27 27 20 28 2 1 Over the counter 50 80 30 502 3 60 404 3 OTC OTCOver the counter
-1-
-1- -2 - 2000 1 1 5-3 - 21 10 2-4 - 5-5 - -6 - -7- -8 - 21 2000 21-9- IT in silico 10-10 - -11 - 20 21 1993 ICH - 12 - 2007 4 1 NIHThe National Institutes of Health2004 NIH NIH 2006 UK Clinical Research
27 ... 1... 1... 2... 4... 4... 5... 11... 11... 11... 11... 15... 15... 17... 19 X A... 21... 23... 25 B... 27... 29... 31... 33... 35... 37... 39... 41... 43... 45... 47... 48 UA NCCU... 48... 50...
Ｎｏ．１９
Views and Actions C Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No n n n n n n pi pii pi pii pi pii n n n PKPD No HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA
,255 7, ,355 4,452 3,420 3,736 8,206 4, , ,992 6, ,646 4,
30 8 IT 28 1,260 3 1 11. 1101. 1102. 1103. 1 3 1,368.3 3 1,109.8 p.5,p.7 2 9,646 4,291 14.5% 10,p.11 3 3,521 8 p.13 45-49 40-44 50-54 019 5 3 1 2,891 3 6 1 3 95 1 1101 1102 1103 1101 1102 1103 1 6,255
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
untitled
2000 2003 2004 DPC Continuum Care 32 IT HIPPA 18 IT MSW MSW MSW 18 HIPPAHealth Insurance Portability and Accountability Act of 1996 33 2002 34 1985 A B C 1020 D E F 35 A B IT A B DPC 36 RUG 19 19 RUGResource
16 Web ICT Web
25 26 3 16 Web ICT Web 22 25 26 3 1. - 1-1.1-1 - 1.2-4 - 2. - 7-2.1-7 - 2.1.1-7 - 2.1.2-12 - 2.2-14 - 2.2.1-14 - 2.2.2-18 - 2.3-20 - 2.3.1-20 - 2.3.2-21 - 2.3.3-24 - 2.3.3.1 PDCA - 24-2.3.3.2-30 - 2.3.3.3
600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN
26 FD 1 1 11 86 88 88 88 90 90 91 91 98 113 125 125 129 130 137 140 141 142 142 144 146 147 150 150 151 151 151 151 151 153 153 154 154 160 171 176 178 178 179 179 180 183 185 185 185 10 187 187 189 193
15 22 22 26 30 2018 36 40 42 44 46 Focus 14 2018 16 2017 17 17 18 19 19 20 20 20 10 2018 15 16-20 Open Up the Future 2020 5,000 1,000 2020 2015 2017 2020 2015 11 30 4,257 4,338 5,000 2016 4 2021 3 5 1,069
履 歴 書
,,,,,, Carboplatin and Monthly Paclitaxel Carboplatin and Weekly Paclitaxel 8(1), 25-34 (2006) Masayoshi KOINUMA, Takahisa YAMANASHI, Miwako KAMEI, Makoto SHIRAGAMI, The realities and Medical Expense of
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
後ろ.indd
2010 p.1-42 2010 7 The relation between food intake of pregnant women and fetal growth -case sutudy- Vol.11 No.3 p.481-4862010 11 The 10th Hamamatsu-kyungpook Joint Medical Symposium, p.54, School of Medicine,Kyugpook
25 FD 2 2 8 72 74 74 81 96 109 109 113 116 121 125 125 127 127 128 131 132 136 136 137 137 137 137 162 162 163 164 164 173 177 182 185 186 187 187 188 191 192 193 193 195 195 197 200 201 203 204 10 205
CHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
HPLC 1M KH 2 PO 4 ph ml Anthranilic acid: AnA 600 ml ml AnA 1.0 ml / min Anthranilic acid= PRESSURE 140 kgf / cm 2
15 10-1-3. 1. HPLC 1M KH 2 PO 4 ph 3.0 50 ml Anthranilic acid: AnA 600 ml 1-1. 350 ml AnA 1.0 ml / min Anthranilic acid=137.14 PRESSURE140 kgf / cm 2 TOSOH TSK-GEL ODS- 80 Ts 1) mg / ml AnA in (φ4.6 250
4703ALL01
473201010 *** (1999) 16 2017 20023 2 1 2 1220 (1999a),(1999b) (1998), (2002) (2003)(1999)(2003) Conjoint Analysis Conjoint Analysis Willingness to PayStandard gamble Time trade-off Rating Scale Willingness
IPSJ SIG Technical Report Vol.2014-EIP-63 No /2/21 1,a) Wi-Fi Probe Request MAC MAC Probe Request MAC A dynamic ads control based on tra
1,a) 1 1 2 1 Wi-Fi Probe Request MAC MAC Probe Request MAC A dynamic ads control based on traffic Abstract: The equipment with Wi-Fi communication function such as a smart phone which are send on a regular
APU win-win
APU win-win ACPA PMBOK PMBOK Project Management Institute, PMI Project Management Body of Knowledge PMBOK RR R R.%.% PMI PMBOK PMI PMBOK PMBOK PMBOK PMBOK PMBOK PDCAPlan- Do-Check-ActPMBOK PDCA PMBOK PDCA
CRA2381-A
AVIC-500/AVIC-5KV /AVIC-505 1 2 63 4 155 11 1 2 3 a a a 3 C O N T E N T S 4 5 6 7 8 1 1 9 10 1 11 12 1 13 14 1 q w e 15 16 2 2 17 18 2 19 20 2 21 22 2 23 24 2 25 26 2 27 28 2 29 30 2 31 32 3 3 33 34 3
28 28 29 3 ... 5... 5... 6... 6... 8... 8... 10..... 10..... 10..... 10..... 10..... 11..... 13... 17..... 17..... 17..... 17..... 18..... 18..... 19..... 21... 25..... 25..... 25... 36..... 36..... 36.....
UNEP sustainable consumption sustainable production 1980 rebound effect rebound effect IO-EHA 1 CO 2 rebound effect CO 2 rebound effect
2005 3 Discussion Paper No. 95 UNEP sustainable consumption sustainable production 1980 rebound effect rebound effect IO-EHA 1 CO 2 rebound effect CO 2 rebound effect 2005 3 1 (Environmental Household
Taro9-医薬品目次２０１２－１.PDF
5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20
A Study of Effective Application of CG Multimedia Contents for Help of Understandings of the Working Principles of the Internal Combustion Engine (The
A Study of Effective Application of CG Multimedia Contents for Help of Understandings of the Working Principles of the Internal Combustion Engine (The Learning Effects of the Animation and the e-learning
IPSJ SIG Technical Report Vol.2016-CE-137 No /12/ e β /α α β β / α A judgment method of difficulty of task for a learner using simple
1 2 3 4 5 e β /α α β β / α A judgment method of difficulty of task for a learner using simple electroencephalograph Katsuyuki Umezawa 1 Takashi Ishida 2 Tomohiko Saito 3 Makoto Nakazawa 4 Shigeichi Hirasawa
図 1 緩和ケアチーム情報共有データベースの患者情報画面 1 患者氏名, 生年月日, 性別, 緩和ケアチームへの依頼内容について,2 入退院記録, 3カンファレンス ラウンド実施一覧,4 問題点のリスト,5 介入内容の記録. 図 2 緩和ケアチームカンファレンス ラウンドによる患者評価入力画面 (
2015; 10(2): 901 5 活動報告 緩和ケアチームデータベースの改良に向けた取り組み 渡邊裕之 1,4), 江藤美和子 2,4) 3,4), 山﨑圭一 1 2 3 4 受付日 2014 年 9 月 10 日 / 改訂日 2015 年 1 月 29 日 / 受理日 2015 年 2 月 3 日 2011 年に, ベルランド総合病院緩和ケアチーム ( 以下,PCT) で構築した PCT 情報共有データベース
2011 2014 19 22-1 - - 2 - - 3 - - 4 - HIV HIV - 5 - SCU - 6 - ICUHCU NICU NICU HCU NICU ALSO - 7 - T-MRI FISH - 8 - ME NST - 9 - - 10 - da Vinci C C C DPC - 11 - C C C C C C - 12 - C C D D DPC D D - 13
untitled
CTCAE v3.0 JCOG/JSCO v1.0 Instructions and Guidelines for Japanese CTCAE v3.0 by JCOG and JSCO JCOG JCOG JCOG JCOG 2004 5 13 2004 7 1 2004 10 1 2004 10 27 JCOG http://www.jcog.jpjcog 0. 0.1. NCI Common
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
16 3 4 2 SSI 7 S 5 1 2 SSI a b 1 28 3 T MIC 2 or 32 3 8 2 3 16 TQM SIR 3 CMZ or CEZ bundle DPC H1820 16 SSI 1687 SSI 4953 1 2 2 8 3 4 3 51 3 7 3 10 1
9 9 22 DPC SSI 2 1 SSI 2 1 16 3 4 2 SSI 7 S 5 1 2 SSI a b 1 28 3 T MIC 2 or 32 3 8 2 3 16 TQM SIR 3 CMZ or CEZ bundle DPC H1820 16 SSI 1687 SSI 4953 1 2 2 8 3 4 3 51 3 7 3 10 1 2 1 2 3 1 DPC 3 DPC DPC
Kobe University Repository : Kernel タイトル Title 著者 Author(s) 掲載誌 巻号 ページ Citation 刊行日 Issue date 資源タイプ Resource Type 版区分 Resource Version 権利 Rights DOI JaLCDOI URL グローバル市場における後発医薬品との競争 : 内資系大手製薬企業 4 社の事例研究
GB 3rd edition final.ppt
Complementary and Alternative Medicine (National Center for Complementary and Alternative Medicine; NCCAM) Complementary and alternative medicine is a group of diverse medical and health care systems,
untitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
CEO 2017.10.30 Agenda Agenda ) 2000 2000 10 ~ ~ GLP: Good Laboratory Practice GCP: Good Clinical Practice GMP: Good Manufacturing Practice GPSP: Good Post-marketing Study 1 10,000 Practice GLP GMP GCP
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
The Indirect Support to Faculty Advisers of die Individual Learning Support System for Underachieving Student The Indirect Support to Faculty Advisers of the Individual Learning Support System for Underachieving
No.2
Views and Actions MR MR OPIR OPIR Office of Pharmaceutical Industry Research Points of Views GCP GCP GCP GCP CRC CRC CRC CRC CRC IRB CRC CRC CRC patientoriented patientoriented IT CRC patient oriented
200812 06 Development 2
200812 06 Development 2 200812 06 Research and Clinical Center for Child Development 4 (CP) MR MR, MR, MR( PDD, PDD, ADHD, 200812 06 Research and Clinical Center for Child Development 5 LD LD ADHD ADHD
() CT X X Ver.5 64 ( 3.0 % / 24,, 25 H23 1 Dr 24 24 2 1 25 RI RI ICU 24 25 B 4500 13000 AHA-PALS 5 PALS 24 25 24 25 24 ICU 24 25 24 1 VA VA 25 25 VA HD VA 20 150 () () 25 2 24 25 24 24 414 102 25
untitled
11 Management & Technology for Creative Kyoto 2012. 10 2012. 10 Management & Technology for Creative Kyoto 12 13 Management & Technology for Creative Kyoto 2012. 10 2012. 10 Management & Technology for
- 1 -
- 1 - 35:261-262 2005.12 35:153-154 2005.12-2 - 15500383 15-17 2006.3 [] 1 17(5):161-165 2005.5 32(3):130-134 2005.6 Synovial fringe 1 22(3):322 2005.10 Pancoast 56(13):1663-1666 2005.12 [] 22(5):788-795
Kyoto Sangyo University Slywotzky and Morrison 1997 Slywotzky ,2001, ,550 6, ,87
1 2008 2 Slywotzky and Morrison 1997 Slywotzky 20021999 20041999,2001,2006 1999 3 3 1997 2007 10 2,550 6,674 2.6 1 2007 2,878 2 12007 2 15 658 39 20 3 13 2 OTC 8 2,294 6 6,108 3 6,911 4 10 15,900 5 9 17
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical